BenaGene Introduction
How It Works
Anti-Aging Life Extension
Glucose Management
Weight Management
Genomic Changes
Contact Us
benaGene News
Online Distributors





 benaGene News 

November 2009

Freely Available journal article at "Open Longevity Science" (2009) "Oxaloacetic Acid Supplementation as a Mimic of Calorie Restriction." In the article, we review not only our previously published work, but also the work of many other researchers that document oxaloacetate supplementation to reduce fasting glucose levels, it's action as a powerful antioxidant, protection of mitochondrial DNA (a big plus), and protection of eye, brain and pancreas tissues. There is also in-vitro evidence that very small amounts of oxaloacetate builds intracellular "junk" within human lung cancer cells which prevents them from reproducing, even after the oxaloacetate is removed from the cells. Normal cells continue to divide normally with oxaloacetate. We further provide a case study of a 73 year old diabetic woman who reduced and stabilized her glucose levels by taking oxaloacetic acid. In 75 days she reduced her fasting glucose levels by 24%, reduced her insulin resistance by 34%, and reduced the amplitude of her glucose "swings" by 55%. Persons with normal glucose functioning will see an increase in glucose uptake by the muscle tissue, and only a small drop in fasting glucose levels (fyi, mine was about 8%). Fasting glucose levels tend to stabilize even in persons with normal glucose functioning. The information all points to the use of oxaloacetic acid as a calorie restriction mimetic.

Download for free: http://www.bentham.org/open/tolsj/openaccess2.htm and click on "Hot Topic: Calorie Restriction Mimetics".  This will bring you to a page where you can download the article for free.

Oxaloacetate shown to increase lifespan through AMPK and FOXO/DAF16

October 2009


The research out of UCSD and UCLA in "Aging Cell" documents that excess oxaloacetate supplemented to C. elegans causes an increase in lifespan of 25%, p<< 0.001.  The article also strongly suggests that the molecular pathways activated by oxaloacetate supplementation are the same pathways as are activated in dietary restriction.  The article suggests that the numerous benefits of dietary restriction may be achievable with oxaloacetic acid supplementation.


See Link for Aging Cell Journal Article


Calorie Restriction Significantly increases the Lifespan and Health-span of Primates

August 2009


Aging scientists have known for some time that reducing calories to levels 20 to 40% below what animals normally would eat results in increases in lifespan and decreases in many major diseases in yeast, worms, flies, guppies, zebra fish, spiders, mice, rats and dogs.  We now get to add primates to the list of animals that are proven to live significantly longer with calorie restriction, thanks to a twenty-year study of monkeys at the University of Wisconsin.

Calorie restriction studies in human volunteers have shown many of the same benefits as are seen in the monkey study, including reductions in cardiovascular risk factors and reductions in fasting glucose levels.  Some of these same benefits are also seen with calorie restriction mimetic compounds, which simulate the molecular pathways of calorie restriction without the necessary draconian cut in calorie consumption.  The twenty-year monkey study gives us even more reason to either practice calorie restriction or consume a calorie restriction mimetic compound such as benaGene.

Caloric Restriction Delays Disease Onset and Mortality in Rhesus Monkeys


NIA "Interventions" study identifies that Rapamycin Increases the lifespan of Normally Fed Mice.

August 2009


As part of Cohort 2 of the Interventions study, the transplant drug Rapamycin increased the lifespan of normally fed mice.  Unlike resveratrol, which did not increase the lifespan of normally fed mice, Rapamycin significantly increased both male and female lifespan.  Rapamycin has been documented to change the expression levels of several genes.  This molecular pathway is called the "Target of Rapamycin" or mTOR pathway.  Reductions in the mTOR pathway have been previously shown to increase lifespan in invertibrates, and now has also been shown to increase lifespan in mice.  Unfortunately, Rapamycin has several side effects, which include systemic reductions in the immune system which your body uses to fight off disease.  Because of these strong side effects, Rapamycin should not be used as an anti-aging drug. 


Rapamycin fed late in life extends lifespan in genetically heterogeneous mice


Note that benaGene is in Cohort 4 of the NIA "Interventions" study.  We look forward to positive results from this study without the side effects of rapamycin.


NIA begins Aging "Intervention" testing with benaGene

September 2007

Large scale testing of benaGene's active ingredient begins this week within the National Institute of Aging (NIA) "Interventions" program.  The NIA tests a few compounds per year in an attempt to extend the lifespan and health span of mammals (mice).  Results of this large study will be published with Terra Biological's personnel.

More on the Intervention Testing Program can be found at the following web site: http://www.nia.nih.gov/ResearchInformation/ScientificResources/InterventionsTestingProgram.htm

Increases in NAD+ Levels Dictate Cell Survival

September 2007

"A major cause of cell death caused by genotoxic stress is thought to be due to the depletion of NAD+ from the nucleus and the cytoplasm."

"It is generally accepted that depletion of NAD+ stimulates a number of proapoptotic pathways, including the relocalization of AIF from the outer mitochondrial membrane to the nucleus."

Recearchers at Harvard, Cornell and the NIA examine mitochondrial levels of NAD+.  It is not certain if the NAD+ in the mitochondria come from genes within the Mitochondria or from import from the cytoplasm.  It may be both.

See: http://www.cell.com/content/article/abstract?uid=PIIS0092867407009737

Note from Terra Biological: benaGene is thought to work by increases in the NAD+ levels.

Increases in NAD increase lifespan again....  May 6, 2007

Researchers at the Dartmouth University show that a natural product that increases NAD also increases lifespan in yeast.  See http://dms.dartmouth.edu/news/2007_h1/print/03may2007_brenner.html

This is no surprise to benaGene users, which have been increasing their NAD levels for some time now....


benaGene Joins the M Prize competition  April 15, 2007

Terra Biological has become a competitor in the M-Prize competition to increase the lifespan of mice.  See http://www.mprize.org/index.php?pagename=newsdetaildisplay&ID=119


benaGene discussed at Edmonton Aging Conference March 30, 2007

Terra Biological LLC will be presenting a poster at the Edmonton aging conference in Canada on March 30-31, 2007.  Additional information can be obtained at www.edmontonagingsymposium.com/

Age Related News Release February 16, 2007

The lifespan of human cells has been increased by up to 70% by increasing the amount of NAD+ in the cells.  In a paper by Eric van der Veer and others at the London Health Sciences Centre, genetic engineering was used to increase the enzyme levels of phosphoribosyltransferase (which recycle NAD+ from nicotimamide) and there by increase NAD+ levels.

A copy of the paper can be obtained at http://www.jbc.org/cgi/doi/10.1074/jbc.C700018200

Van der Veer, E. et al, "Extension of Human Cell Lifespan by Nicotinamide Phosphoribosyltransferase" 2007 The Journal of Biological Chemistry

Age Related News Release January 3, 2007

Increasing the NAD+ levels after stroke reduces brain cell death in rats by over 70%. NAD+ levels support the activity of the DNA repair enzyme PARP-1, which is used when brain cells are damaged.  After a stroke, brain cells quickly deplete NAD+ levels because of upregulation of PARP-1, and the DNA repair rate drops.  Addition of external NAD+ greatly reduced the damage from stroke. 

More information at:  http://www.eurekalert.org/pub_releases/2006-12/uoc--ntp122806.php

News Release December 30, 2006

Interventions Testing Program

Good News, benaGene is currently making it's way through the National Institute on Aging, Interventions Testing Program application process.  The news so far is,

"Your proposal to the NIA Interventions Testing Program (ITP) has been reviewed through a two-tier review and prioritization process, and was given a high priority for inclusion in the next round of testing."

NIA/NIH has some additional questions that we have to answer before we will know if benaGene is fully accepted into the program.  It looks good so far....

More on the Intervention Testing Program can be found at the following web site: http://www.nia.nih.gov/ResearchInformation/ScientificResources/InterventionsTestingProgram.htm


Site Mailing List 
These statements have not been evaluated by the FDA. The product is not intended to diagnose, treat, cure, or prevent any disease.

@2009 all information
Terra Biological LLC

Site Powered By
    WebBizBuilder Site Manager
    Online web site design